{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:06:50Z","timestamp":1775279210297,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["POCI\/01\/0145\/FEDER\/007728"],"award-info":[{"award-number":["POCI\/01\/0145\/FEDER\/007728"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003381","name":"Minist\u00e9rio da Educa\u00e7\u00e3o e Ci\u00eancia","doi-asserted-by":"publisher","award":["PT2020 UID\/MULTI\/04378\/2013"],"award-info":[{"award-number":["PT2020 UID\/MULTI\/04378\/2013"]}],"id":[{"id":"10.13039\/501100003381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003381","name":"Minist\u00e9rio da Educa\u00e7\u00e3o e Ci\u00eancia","doi-asserted-by":"publisher","award":["SFRH\/BD\/110683\/2015"],"award-info":[{"award-number":["SFRH\/BD\/110683\/2015"]}],"id":[{"id":"10.13039\/501100003381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003381","name":"Minist\u00e9rio da Educa\u00e7\u00e3o e Ci\u00eancia","doi-asserted-by":"publisher","award":["SFRH\/BPD\/99124\/2013"],"award-info":[{"award-number":["SFRH\/BPD\/99124\/2013"]}],"id":[{"id":"10.13039\/501100003381","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cbi.2018.04.027","type":"journal-article","created":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T13:24:25Z","timestamp":1524835465000},"page":"75-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Effect of the alkyl group in the piperazine N-substitution on the therapeutic action of rifamycins: A drug-membrane interaction study"],"prefix":"10.1016","volume":"289","author":[{"given":"Em\u00edlio V.","family":"Lage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salette","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2018.04.027_bib1","series-title":"Global Tuberculosis Report 2017","author":"WHO","year":"2017"},{"key":"10.1016\/j.cbi.2018.04.027_bib2","first-page":"1907","article-title":"Rifampicin, a general review","volume":"21","author":"Binda","year":"1971","journal-title":"Arzneim. Forsch."},{"key":"10.1016\/j.cbi.2018.04.027_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tube.2010.02.001","article-title":"Rifamycins-obstacles and opportunities","volume":"90","author":"Aristoff","year":"2010","journal-title":"Tuberculosis"},{"key":"10.1016\/j.cbi.2018.04.027_bib4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cbi.2018.04.027_bib5","first-page":"1053","article-title":"Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides","volume":"23","author":"Chen","year":"2009","journal-title":"Infect. Dis. Clin."},{"key":"10.1016\/j.cbi.2018.04.027_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1128\/CMR.00034-09","article-title":"Rifampin combination therapy for nonmycobacterial infections","volume":"23","author":"Forrest","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.cbi.2018.04.027_bib7","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a027011","article-title":"Rifamycins, alone and in combination","volume":"6","author":"Rothstein","year":"2016","journal-title":"Cold Spring Harbor perspectives in medicine"},{"key":"10.1016\/j.cbi.2018.04.027_bib8","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3390\/ph5111210","article-title":"The role of transport mechanisms in Mycobacterium Tuberculosis drug resistance and tolerance","volume":"5","author":"Sarathy","year":"2012","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cbi.2018.04.027_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ijantimicag.2009.12.017","article-title":"Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns","volume":"35","author":"Tupin","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.cbi.2018.04.027_bib10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S2213-2600(15)00063-6","article-title":"Tuberculosis treatment and management\u2013an update on treatment regimens, trials, new drugs, and adjunct therapies","volume":"3","author":"Zumla","year":"2015","journal-title":"The Lancet. Respir. Med."},{"key":"10.1016\/j.cbi.2018.04.027_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1359-6446(05)03626-3","article-title":"New drug candidates and therapeutic targets for tuberculosis therapy","volume":"11","author":"Zhang","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cbi.2018.04.027_bib12","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.2174\/1381612043383287","article-title":"In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infections","volume":"10","author":"Lounis","year":"2004","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.cbi.2018.04.027_bib13","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.drudis.2008.09.004","article-title":"New anti-tuberculosis drugs in clinical trials with novel mechanisms of action","volume":"13","author":"Rivers","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.cbi.2018.04.027_bib14","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1541","article-title":"Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice","volume":"148","author":"Ji","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.cbi.2018.04.027_bib15","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1128\/AAC.40.12.2809","article-title":"Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis","volume":"40","author":"Kelly","year":"1996","journal-title":"AAC (Antimicrob. Agents Chemother.)"},{"key":"10.1016\/j.cbi.2018.04.027_bib16","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1164\/ajrccm.161.5.9904090","article-title":"Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens","volume":"161","author":"Daniel","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cbi.2018.04.027_bib17","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1128\/AAC.45.12.3482-3486.2001","article-title":"Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice","volume":"45","author":"Lounis","year":"2001","journal-title":"AAC (Antimicrob. Agents Chemother.)"},{"key":"10.1016\/j.cbi.2018.04.027_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040344","article-title":"Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model","volume":"4","author":"Rosenthal","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.cbi.2018.04.027_bib19","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.7164\/antibiotics.34.1026","article-title":"Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative","volume":"34","author":"Arioli","year":"1981","journal-title":"J. Antibiot."},{"key":"10.1016\/j.cbi.2018.04.027_bib20","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/infdis\/jis461","article-title":"Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium","volume":"206","author":"Dorman","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cbi.2018.04.027_bib21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","article-title":"Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial","volume":"191","author":"Dorman","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cbi.2018.04.027_bib22","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1164\/ajrccm.157.6.9707037","article-title":"Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report","volume":"157","author":"Tam","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cbi.2018.04.027_bib23","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","article-title":"Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial","volume":"360","author":"Benator","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cbi.2018.04.027_bib24","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","article-title":"Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium","volume":"353","author":"Vernon","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cbi.2018.04.027_bib25","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1086\/508278","article-title":"Rifapentine for the treatment of pulmonary tuberculosis","volume":"43","author":"Munsiff","year":"2006","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.cbi.2018.04.027_bib26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/00003495-199856040-00008","article-title":"Rifapentine","volume":"56","author":"Jarvis","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.cbi.2018.04.027_bib27","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1164\/rccm.200311-1612OC","article-title":"Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy","volume":"169","author":"Weiner","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cbi.2018.04.027_bib28","first-page":"73","article-title":"A comparative study of rifapentine treatment and three years follow-up on initial pulmonary tuberculous, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi","volume":"16","author":"He","year":"1993","journal-title":"Chin. J. Tuberc. Respir. Dis."},{"key":"10.1016\/j.cbi.2018.04.027_bib29","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1345\/aph.18450","article-title":"Rifapentine: its role in the treatment of tuberculosis","volume":"33","author":"Temple","year":"1999","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.cbi.2018.04.027_bib30","series-title":"Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens (S31\/A5349)","author":"TBTC","year":"2015"},{"key":"10.1016\/j.cbi.2018.04.027_bib31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.cbi.2018.04.027_bib32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1378\/chest.115.1.12","article-title":"Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids","volume":"115","author":"Peloquin","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.cbi.2018.04.027_bib33","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1128\/AAC.43.5.1230","article-title":"Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study","volume":"43","author":"Keung","year":"1999","journal-title":"AAC (Antimicrob. Agents Chemother.)"},{"key":"10.1016\/j.cbi.2018.04.027_bib34","doi-asserted-by":"crossref","first-page":"11635","DOI":"10.1021\/jp303725j","article-title":"Molecular interaction of Rifabutin on model lung surfactant monolayers","volume":"116","author":"Pinheiro","year":"2012","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.cbi.2018.04.027_bib35","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbamem.2009.11.024","article-title":"Infrared reflection-absorption spectroscopy: principles and applications to lipid-protein interaction in Langmuir films","volume":"1798","author":"Mendelsohn","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cbi.2018.04.027_bib36","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/cphc.201100080","article-title":"Probing the functionalization of gold surfaces and protein adsorption by PM-IRRAS","volume":"12","author":"de Oliveira","year":"2011","journal-title":"ChemPhysChem : a European Journal of chemical physics and physical chemistry"},{"key":"10.1016\/j.cbi.2018.04.027_bib37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/jm301116j","article-title":"Differential interactions of rifabutin with human and bacterial membranes: implication for its therapeutic and toxic effects","volume":"56","author":"Pinheiro","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2018.04.027_bib38","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1016\/S0006-3495(96)79523-1","article-title":"Molecular packing of cord factor and its interaction with phosphatidylinositol in mixed monolayers","volume":"71","author":"Almog","year":"1996","journal-title":"Biophys. J."},{"key":"10.1016\/j.cbi.2018.04.027_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.chemphyslip.2008.01.004","article-title":"Cholesteroid nature of free mycolic acids from M. tuberculosis","volume":"152","author":"Benadie","year":"2008","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.cbi.2018.04.027_bib40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/jp962288d","article-title":"Quantitative determination of molecular chain tilt angles in monolayer films at the air\/water Interface:\u2009 infrared reflection\/absorption spectroscopy of behenic acid methyl ester","volume":"101","author":"Flach","year":"1997","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.cbi.2018.04.027_bib41","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1582-4934.2008.00281.x","article-title":"Membranes: a meeting point for lipids, proteins and therapies","volume":"12","author":"Escriba","year":"2008","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.cbi.2018.04.027_bib42","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1146\/annurev.physchem.58.032806.104619","article-title":"Collapse mechanisms of Langmuir monolayers","volume":"59","author":"Lee","year":"2008","journal-title":"Annu. Rev. Phys. Chem."},{"key":"10.1016\/j.cbi.2018.04.027_bib43","doi-asserted-by":"crossref","first-page":"8351","DOI":"10.1021\/la201482n","article-title":"On the low surface tension of lung surfactant","volume":"27","author":"Zhang","year":"2011","journal-title":"Langmuir : the ACS journal of surfaces and colloids"},{"key":"10.1016\/j.cbi.2018.04.027_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cis.2005.05.001","article-title":"Interfacial properties of pulmonary surfactant layers","volume":"117","author":"Wustneck","year":"2005","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.cbi.2018.04.027_bib45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jcis.2011.04.018","article-title":"Biophysical investigation of the interfacial properties of cationic fluorocarbon\/hydrocarbon hybrid surfactant: mimicking the lung surfactant protein C","volume":"360","author":"Aydogan","year":"2011","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.cbi.2018.04.027_bib46","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1002\/cphc.200900328","article-title":"Effects of fullerenes on phospholipid membranes: a Langmuir monolayer study","volume":"10","author":"Wang","year":"2009","journal-title":"ChemPhysChem : a European journal of chemical physics and physical chemistry"},{"key":"10.1016\/j.cbi.2018.04.027_bib47","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1021\/la201600y","article-title":"NSAIDs interactions with membranes: a biophysical approach","volume":"27","author":"Nunes","year":"2011","journal-title":"Langmuir : the ACS journal of surfaces and colloids"},{"key":"10.1016\/j.cbi.2018.04.027_bib48","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/0250-474X.33142","article-title":"Atypical log D profile of rifampicin","volume":"69","author":"Mariappan","year":"2007","journal-title":"Indian J. Pharmaceut. Sci."},{"key":"10.1016\/j.cbi.2018.04.027_bib49","unstructured":"National Center for Biotechnology Information. PubChem Compound Database; CID=5381226, https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5381226 (accessed Sept. 28, 2017)."},{"key":"10.1016\/j.cbi.2018.04.027_bib50","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jac\/dku457","article-title":"Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents","volume":"70","author":"Lakshminarayana","year":"2015","journal-title":"JAC (J. Antimicrob. Chemother.)"},{"key":"10.1016\/j.cbi.2018.04.027_bib51","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1021\/la015702w","article-title":"Influence of pulmonary surfactant protein B on model lung surfactant monolayers","volume":"18","author":"Bringezu","year":"2002","journal-title":"Langmuir : ACS J. surfaces and colloids"},{"key":"10.1016\/j.cbi.2018.04.027_bib52","doi-asserted-by":"crossref","first-page":"15188","DOI":"10.1021\/bi701831f","article-title":"Structure and orientation of pancreatic colipase in a lipid environment: PM-IRRAS and Brewster angle microscopy studies","volume":"46","author":"Allouche","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.cbi.2018.04.027_bib53","doi-asserted-by":"crossref","first-page":"12968","DOI":"10.1021\/la9017932","article-title":"Studies of dipalmitoylphosphatidylcholine (DPPC) monolayers embedded with endohedral metallofullerene (Dy@C82)","volume":"25","author":"Wang","year":"2009","journal-title":"Langmuir : ACS J. surfaces and colloids"},{"key":"10.1016\/j.cbi.2018.04.027_bib54","doi-asserted-by":"crossref","first-page":"18902","DOI":"10.1021\/la102842a","article-title":"Reorganization and caging of DPPC, DPPE, DPPG, and DPPS monolayers caused by dimethylsulfoxide observed using Brewster angle microscopy","volume":"26","author":"Chen","year":"2010","journal-title":"Langmuir : ACS J. surfaces and colloids"},{"key":"10.1016\/j.cbi.2018.04.027_bib55","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.bbamem.2012.09.015","article-title":"Interplay of mycolic acids, antimycobacterial compounds and pulmonary surfactant membrane: a biophysical approach to disease","volume":"1828","author":"Pinheiro","year":"2013","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279718301200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279718301200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T19:46:26Z","timestamp":1762112786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279718301200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":55,"alternative-id":["S0009279718301200"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2018.04.027","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of the alkyl group in the piperazine N-substitution on the therapeutic action of rifamycins: A drug-membrane interaction study","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2018.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}